🌍·1d agodiscovery
CG Oncology Announces Lancet Oncology Publication of Phase 3 BOND-003 Cohort C Results for Cretostimogene in High-Risk BCG-Unresponsive Bladder Cancer
Publisher
Q
Quiver Quantitative
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Quiver Quantitative
- Region
- Global
- Scope
- discovery
- Published
- July 28, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: Quiver Quantitative
Scope: discovery
Related coverage
More related coverage
LatestLY/8h ago
Maharashtra FDA Suspends Licences of These 5 Clubs in Mumbai Over Food Safety Violations; Check Names Here
Politico/8h ago
FDA panel to consider previously spurned drugs
PR Newswire/8h ago
Ono Pharmaceutical partners with Phylo to embed agentic AI with every discovery scientist
MarketBeat/8h ago